SAN FRANCISCO, Aug. 17 /PRNewswire/ -- Sofinnova Ventures, a San Francisco venture firm investing in early-stage life science and information technology companies, announced today that Nicola Campbell, Ph.D. has joined the firm as a life science partner. Her investment focus will be on early-stage investment opportunities in the sectors of drug discovery and pharmaceutical and biologic development. Most recently, Campbell was a principal with BA Venture Partners, where she focused on mid-stage investment opportunities in drug discovery and product-based companies. She joined BAVP from Burrill & Co, a life science merchant banking firm focusing on biotechnology venture capital. Prior to joining the venture community, Campbell spent four years at Genentech in both business development and scientific roles. She developed strategic partnerships with Actelion and Gene Logic, among others, and was a member of the Cardiovascular Therapeutic Area Team responsible for the strategic vision of that franchise. She initially joined Genentech as an immunologist in the research department. "I have known Mike Powell and Jim Healy for years, and worked with them on numerous projects and deals," said Campbell. "Sofinnova has a terrific team, all around, a strong LP base, and continues to strengthen its reputation across communities. I'm really delighted to be part of their team." "Our collaborative history with Nicola makes her a natural fit for our team," commented Jim Healy, M.D., Ph.D., managing director, Sofinnova Ventures. "And her background makes her a natural asset to our team. She has an excellent track record as a venture capitalist, and as a business development executive and clinical immunologist with Genentech. She has a well-rounded skill set and a terrific network across the industry. She's a real catch." Campbell received her Ph.D. in Molecular and Cellular Immunology from Mount Sinai Medical Center, during which she was a recipient of the American Gastroenterology Association's Outstanding Research Award. She completed her MS in Medical Sciences from the Mount Sinai School of Medicine, and received her BS in Human Biology from the University of Guelph in Ontario, Canada, where she was awarded the Dean's Scholarship for Academic Excellence. About Sofinnova Ventures San Francisco-based Sofinnova Ventures, founded in 1974, has $600 million under management. The firm emphasizes a diversified investment strategy through financing seed and early-stage companies in the life science and information technology sectors. Historically, Sofinnova has been associated with leading companies such as Biogen, Collagen, Genentech, Printronix, Tandem Computers and Tandon. More recently, Sofinnova invested in Actelion, Aviron, Element-14 (Broadcom), InterMune, Millennium Pharmaceuticals, Phone.com, Premisys, Seattle Genetics and Tumbleweed Communications. For more information, visit www.sofinnova.com.
SOURCE Sofinnova Ventures